CN109438510B - P-炔基磷酸酯类化合物的合成方法 - Google Patents

P-炔基磷酸酯类化合物的合成方法 Download PDF

Info

Publication number
CN109438510B
CN109438510B CN201811494343.2A CN201811494343A CN109438510B CN 109438510 B CN109438510 B CN 109438510B CN 201811494343 A CN201811494343 A CN 201811494343A CN 109438510 B CN109438510 B CN 109438510B
Authority
CN
China
Prior art keywords
substituted
phosphate compounds
alkynyl
cdcl
synthesizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811494343.2A
Other languages
English (en)
Other versions
CN109438510A (zh
Inventor
赵子剑
连琰
朱桥
罗正红
张莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huaihua University
Original Assignee
Huaihua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huaihua University filed Critical Huaihua University
Priority to CN201811494343.2A priority Critical patent/CN109438510B/zh
Publication of CN109438510A publication Critical patent/CN109438510A/zh
Application granted granted Critical
Publication of CN109438510B publication Critical patent/CN109438510B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明涉及一种P‑炔基磷酸酯类化合物的合成方法,包括如下步骤:在保护气体的氛围下,P‑酰乙基磷酸酯类化合物、吡啶盐和有机碱在有机溶剂中进行反应,所述P‑炔基磷酸酯类化合物具有通式1所示结构,所述P‑酰乙基磷酸酯类化合物具有通式2所示结构,
Figure DDA0001896484720000011
其中,R1和R2分别独立地选自:烷基、取代的烷基、芳基、取代的芳基、杂芳基、取代的杂芳基;所述有机碱为分子中不含金属的胺类化合物。该方法不需要用到金属催化剂,反应条件温和,并且反应的产率高。

Description

P-炔基磷酸酯类化合物的合成方法
技术领域
本发明涉及化学合成技术领域,特别是涉及一种P-炔基磷酸酯类化合物的合成方法。
背景技术
炔基磷酸酯是一种可以转化为其他杂环化合物的关键中间体,在有机合成及药物合成中具有重要意义,且其本身具有多种生物活性和光电导性。因而,炔基磷酸酯的制备引起了人们广泛的研究兴趣。典型的合成方法为:将六甲基二硅基氨基锂(LiHMDS)、氯磷酸二乙酯[ClP(O)(OEt)2]和LiHMDS依次加入到P-酰乙基磷酸酯的无水溶液中反应;在加入LiHMDS反应时的温度控制在-10~-78℃;加入ClP(O)(OEt)2后,体系升温至10~30℃下反应,通过反应获得各种不同取代的炔基磷酸酯类化合物。然而,在金属催化剂存在下,该反应成本高、反应条件苛刻、产率低。因此,人们一直致力于寻求在不存在任何过渡金属催化剂的情况下高产率制备炔基磷酸酯的方法。
发明内容
基于此,本发明提供了一种新的P-炔基磷酸酯类化合物的合成方法,该方法不需要用到金属催化剂,反应条件温和,并且反应的产率高。
具体技术方案如下:
一种P-炔基磷酸酯类化合物的合成方法,包括如下步骤:
在保护气体的氛围下,P-酰乙基磷酸酯类化合物、吡啶盐和有机碱在有机溶剂中进行反应,
所述P-炔基磷酸酯类化合物具有通式1所示结构,所述P-酰乙基磷酸酯类化合物具有通式2所示结构,
Figure BDA0001896484700000011
其中,R1和R2分别独立地选自:烷基、取代的烷基、芳基、取代的芳基、杂芳基、取代的杂芳基;
所述有机碱为分子中不含金属的胺类化合物。
在其中一些实施例中,R1和R2分别独立地选自:C1-10烷基、取代的C1-10烷基、C6-10芳基、取代的C6-10芳基、C1-9杂芳基、取代的C1-9杂芳基。
在其中一些实施例中,R1选自:C6-10芳基、R4取代的C6-10芳基、C1-9杂芳基、R4取代的C1-9杂芳基;R2选自:C1-10烷基、R4取代的C1-10烷基;R4选自:卤素、C1-4烷基、C1-4烷氧基、苯基。
在其中一些实施例中,R1选自:苯基、卤素取代的苯基、甲基取代的苯基、甲氧基取代的苯基、3、4-二亚甲氧基苯基、联苯基、萘基、甲氧基取代的萘基、呋喃基、噻吩基;R2选自:C1-4烷基。
在其中一些实施例中,所述吡啶盐选自2-氯-1-甲基碘化吡啶、1,2-二甲基碘化吡啶中的至少一种。
在其中一些实施例中,所述有机碱为三乙胺。
在其中一些实施例中,所述有机溶剂选自二氯甲烷、二氯乙烷中的至少一种。
在其中一些实施例中,所述P-酰乙基磷酸酯类化合物、所述吡啶盐和所述有机碱的摩尔比为:1:0.8-1.2:0.8-1.2。
在其中一些实施例中,所述反应的温度为10-40℃。
在其中一些实施例中,所述反应的时间为2-4小时。
在其中一些实施例中,所述保护气体为氮气。
本发明的新的P-炔基磷酸酯类化合物的合成方法与过去已经报道的方法相比,具有以下优点和有益效果:
(1)实用性好,反应条件温和,为室温反应,易于实现含有各种不同取代基组合的P-炔基磷酸酯衍生物的制备;(2)反应收率高(利用本发明的方法以不小于90%的收率制备得到了一系列P-炔基磷酸酯类化合物),并且反应操作简便,为一锅法反应,不需要对中间体进行分离,且目标化合物易分离和提纯;(3)原料廉价易得,不需要使用各种昂贵的芳炔试剂和金属催化剂。
附图说明
图1为化合物2a的1HNMR图谱;
图2为化合物2b的1HNMR图谱;
图3为化合物2c的1HNMR图谱;
图4为化合物2d的1HNMR图谱;
图5为化合物2e的1HNMR图谱;
图6为化合物2f的1HNMR图谱;
图7为化合物2g的1HNMR图谱;
图8为化合物2h的1HNMR图谱;
图9为化合物2i的1HNMR图谱;
图10为化合物2j的1HNMR图谱;
图11为化合物2k的1HNMR图谱;
图12为化合物2l的1HNMR图谱;
图13为化合物2m的1HNMR图谱;
图14为化合物2n的1HNMR图谱;
图15为化合物2o的1HNMR图谱;
图16为化合物2p的1HNMR图谱;
图17为化合物2q的1HNMR图谱;
图18为化合物2r的1HNMR图谱;
图19为化合物2s的1HNMR图谱。
具体实施方式
以下结合具体的实施例对本发明做进一步详细的说明。
以下实施例的制备方法如下:
Figure BDA0001896484700000031
1)在氮气保护下,将P-酰乙基磷酸酯类化合物(化合物1,1.0mmol),Mukaiyama试剂(1,2-二甲基碘化吡啶(DMPI))(1.0mmol)、三乙胺(1.0mmol)加入5.0mL二氯甲烷中,搅拌反应3小时。
2)用饱和氯化铵溶液猝灭反应,将混合液注入水中,用乙酸乙酯萃取,有机相用饱和食盐水洗涤,无水硫酸钠干燥,过滤后减压蒸除溶剂;残余物通过硅胶柱层析分离,淋洗液为[石油醚:乙酸乙酯=5:1],得P-炔基磷酸酯类化合物(化合物2)。
实施例1
对苯基乙炔基-P,P-二乙基膦酸酯
P-(2-Phenylethynyl)-diethyl phosphonate(2a)
Figure BDA0001896484700000041
1H NMR(400MHz,CDCl3)δ=7.55(d,J=7.1Hz,2H),7.45(t,J=7.5Hz,1H),7.36(t,J=7.4Hz,2H),4.26–4.18(m,4H),1.40(t,J=7.0Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=132.8,132.7,130.8,128.7,119.7,119.6,99.4,98.9,80.0,77.0,63.4,63.3,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.92ppm.
MS(EI):m/z=89.1(12),102.1(100),165.0(27),182.0(11),195.0(18),210.0(24),238.1(M+,16).
IR(KBr):ν=3058,2986,2934,2908,2187,1489,1444,1390,1265,1163,1024,974,857,760,690,650cm-1.
HRMS(EI):calcd.for[C12H15O3P]+:238.0759,found 238.0753.
实施例2
P-(4-甲基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Methylphenyl)ethynyl)-diethyl phosphonate(2b)
Figure BDA0001896484700000042
1H NMR(400MHz,CDCl3)δ=7.44(d,J=8.1Hz,2H),7.16(d,J=8.0Hz,2H),4.25–4.16(m,4H),2.37(s,3H),1.39(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=141.5,132.7,132.7,129.4,116.5,116.5,100.1,99.5,79.3,76.3,63.3,63.3,21.8,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-4.59ppm.
MS(EI):m/z=103.1(5),116.1(100),179.1(31),196.1(11),209.1(48),224.1(38),237.1(8),252.1(M+,46).
IR(KBr):ν=2985,2934,2905,2184,1508,1266,1158,1023,973,863,815,788,739,608cm-1.
HRMS(EI):calcd.for[C13H17O3P]+:252.0915,found 252.0910.
实施例3
P-(2-甲基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(2-Methylphenyl)ethynyl)-diethyl phosphonate(2c)
Figure BDA0001896484700000043
1H NMR(400MHz,CDCl3)δ=7.50(d,J=7.6Hz,1H),7.32(t,J=7.5Hz,1H),7.22(d,J=7.6Hz,1H),7.17(t,J=7.6Hz,1H),4.26–4.17(m,4H),2.46(s,3H),1.39(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=141.9,141.9,133.19,133.16,130.8,129.9,125.9,119.5,119.4,104.2,98.7,98.2,83.5,80.5,63.4,63.3,20.6,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.87ppm.
MS(EI):m/z=103.1(10),115.1(100),178.1(18),196.1(39),224.1(5),252.1(M+,45).
IR(KBr):ν=2985,2938,2911,2182,1480,1453,1388,1265,1161,1024,974,868,785,762,647cm-1.
HRMS(EI):calcd.for[C13H17O3P]+:252.0907,found 252.0910.
实施例4
P-(3,4-二甲基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(3,4-Dimethylphenyl)ethynyl)-diethyl phosphonate(2d)
Figure BDA0001896484700000051
1HNMR(400MHz,CDCl3)δ=7.32(s,1H),7.29(d,J=7.8Hz,1H),7.11(d,J=7.8Hz,1H),4.24–4.16(m,4H),2.26(s,3H),2.23(s,3H),1.38(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=140.3,137.2,133.63,133.60,130.27,130.25,129.9,116.7,116.7,100.4,99.8,78.9,75.9,63.31,63.25,20.1,19.6,16.24,16.17ppm.
31PNMR(160MHz,CDCl3)δ=-4.48ppm.
MS(EI):m/z=115.1(39),130.1(100),193.1(10),223.1(29),238.1(17),251.1(4),266.1(M+,21).
IR(KBr):ν=2985,2938,2905,2177,1450,1451,1393,1268,1164,1024,972,803,624cm-1.
HRMS(EI):calcd.for[C14H19O3P]+:266.1072,found 266.1066.
实施例5
P-(4-甲氧基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Methoxyphenyl)ethynyl)-diethyl phosphonate(2e)
Figure BDA0001896484700000052
1H NMR(400MHz,CDCl3)δ=7.47(d,J=8.7Hz,2H),6.85(d,J=8.9Hz,2H),4.23–4.13(m,4H),3.80(s,3H),1.37(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=161.5,134.50,134.48,114.3,111.4,111.3,100.2,99.6,78.7,75.7,63.23,63.17,55.5,16.23,16.16ppm.
31PNMR(160MHz,CDCl3)δ=-5.43ppm.
MS(EI):m/z=107(1),119(4),132(100),195(8),225(15),240(16),268(M+,19).
IR(KBr):ν=2982,2938,2905,2182,1603,1509,1295,1257,1172,1024,973,866,837,787cm-1.
HRMS(EI):calcd.for[C13H17O4P]+:268.0864,found 268.0859.
实施例6
P-(2,5-二甲氧基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(2,5-Dimethoxyphenyl)ethynyl)-diethyl phosphonate(2f)
Figure BDA0001896484700000061
1H NMR(400MHz,CDCl3)δ=7.00(d,J=3.1Hz,1H),6.95(dd,J=9.1,3.1Hz,1H),6.81(d,J=9.1Hz,1H),4.27–4.18(m,4H),3.81(s,3H),3.75(s,3H),1.39(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=156.23,156.21,153.1,118.9,118.48,118.45,112.3,109.3,109.2,96.6,96.1,83.5,80.6,63.4,63.3,56.4,56.0,16.24,16.17ppm.
31PNMR(160MHz,CDCl3)δ=-5.78ppm.
MS(EI):m/z=147(59),161(100),224(24),242(68),270(23),283(9),298(M+,77).
IR(KBr):ν=2985,2938,2905,2837,2181,1501,1463,1267,1234,1166,1024,962,804,724,662,611cm-1.
HRMS(EI):calcd.for[C14H19O5P]+:298.0970,found 298.0965.
实施例7
P-(2-(3,4-二亚甲氧基苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(3,4-Methylenedioxyphenyl)ethynyl)-diethyl phosphonate(2g)
Figure BDA0001896484700000062
1H NMR(400MHz,CDCl3)δ=7.10(d,J=8.0Hz,1H),6.95(s,1H),6.77(d,J=8.1Hz,1H),5.99(s,2H),4.23–4.15(m,4H),1.37(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=150.1,147.7,128.43,128.41,112.61,112.55,112.18,112.16,108.8,101.9,99.8,99.3,78.4,75.4,63.32,63.27,16.24,16.17ppm.
31PNMR(160MHz,CDCl3)δ=-5.70ppm.
MS(EI):m/z=133.1(4),146.1(100),209.0(9),239.0(9),254.1(15),282.1(M+,39).
IR(KBr):ν=2986,2907,2179,1604,1505,1489,1443,1339,1253,1207,1131,1101,1029,974,822,754,664,593cm-1.
HRMS(EI):calcd.for[C13H15O5P]+:282.0657,found 282.0652.
实施例8
P-(4-氟苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Fluorophenyl)ethynyl)-diethyl phosphonate(2h)
Figure BDA0001896484700000071
1H NMR(400MHz,CDCl3)δ=7.54(dd,J=8.6,5.4Hz,2H),7.05(t,J=8.6Hz,2H),4.25–4.15(m,4H),1.38(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=165.2,162.7,135.04,135.01,134.95,134.9,116.3,116.1,115.84,115.80,115.78,115.7,98.3,97.7,79.9,77.0,63.4,63.3,16.24,16.18ppm.
31PNMR(160MHz,CDCl3)δ=-6.18ppm.
MS(EI):m/z=107.1(15),120.1(100),183.1(20),200.1(7),213.1(16),228.1(16),256.1(M+,10).
IR(KBr):ν=2985,2935,2905,2189,1599,1508,1267,1236,1160,1024,975,867,843,800,742cm-1.
HRMS(EI):calcd.for[C12H14FO3P]+:256.0665,found 256.0659.
实施例9
P-(4-氯苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Chlorophenyl)ethynyl)-diethyl phosphonate(2i)
Figure BDA0001896484700000072
1H NMR(400MHz,CDCl3)δ=7.47(d,J=8.3Hz,2H),7.33(d,J=8.3Hz,2H),4.25–4.15(m,4H),1.38(t,J=7.0Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=137.2,133.92,133.89,130.90,129.10,118.10,118.00,98.00,97.4,81.0,78.0,63.44,63.38,16.24,16.17ppm.
31PNMR(160MHz,CDCl3)δ=-5.31ppm.
MS(EI):m/z=123.1(10),136.1(100),199.9(19),229.0(20),244.0(18),272.1(M+,17).
IR(KBr):ν=2986,2935,2908,2189,1587,1488,1393,1267,1092,1022,975,858,832,762,701cm-1.
HRMS(EI):calcd.for[C12H14ClO3P]+:272.0369,found 272.0364.
实施例10
P-(4-溴苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Bromophenyl)ethynyl)-diethyl phosphonate(2j)
Figure BDA0001896484700000073
1H NMR(400MHz,CDCl3)δ=7.50(d,J=8.5Hz,2H),7.40(d,J=8.4Hz,2H),4.25–4.16(m,4H),1.39(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=134.1,134.0,132.1,125.6,118.61,118.56,98.0,97.5,81.2,78.2,63.5,63.4,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-6.39ppm.
MS(EI):m/z=101.1(29),169.0(10),180.0(100),260(9),273.0(22),290.1(17),316.1(M+,16).
IR(KBr):ν=2985,2938,2905,2187,1483,1391,1265,1164,1025,976,857,823,761,680cm-1.
HRMS(EI):calcd.for[C12H14BrO3P]+:315.9864,found 315.9858.
实施例11
P-(4-碘苯基乙炔基)-P,P-二乙基膦酸酯
P-(2-(4-Iodophenyl)ethynyl)-diethyl phosphonate(2k)
Figure BDA0001896484700000081
1H NMR(400MHz,CDCl3)δ=7.70(dd,J=10.1,8.4Hz,2H),7.24(dd,J=11.3,5.9Hz,2H),4.23–4.13(m,4H),1.37(m,6H)ppm.
13C NMR(100MHz,CDCl3)δ=138.1,138.0,133.92,133.90,130.8,119.1,119.0,98.2,97.7,81.4,78.4,63.5,63.4,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.30ppm.
MS(EI):m/z=89.1(11),101.1(32),164.1(6),193.1(4),209.1(15),228.0(100),290.9(16),321.0(20),336.0(25),364.0(M+,27).
IR(KBr):ν=2984,2938,2902,2187,1479,1392,1263,1024,975,856,820,760,668cm-1.
HRMS(EI):calcd.for[C12H14IO3P]+:363.9725,found 363.9720.
实施例12
P-联苯基乙炔基-P,P-二乙基膦酸酯
P-(2-Bi phenylethynyl)-diethyl phosphonate(2l)
Figure BDA0001896484700000082
1H NMR(400MHz,CDCl3)δ=7.64–7.55(m,6H),7.44(t,J=7.5Hz,2H),7.37(t,J=7.3Hz,1H),4.28–4.19(m,4H),1.41(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=143.5,139.7,133.2,133.1,129.0,128.3,127.3,127.2,118.3,118.2,99.4,99.0,80.5,77.4,63.4,63.3,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.93ppm.
MS(EI):m/z=165.1(15),178.1(100),241.1(7),271.1(14),286.1(19),314.2(M+,38).
IR(KBr):ν=3036,2982,2938,2908,2184,1485,1265,1023,974,861,765,695,635cm-1.
HRMS(EI):calcd.for[C18H19O3P]+:314.1072,found 314.1066.
实施例13
P-(2-萘基乙炔基)-P,P-二乙基膦酸酯
P-(2-(2-Naphthalenyl)ethynyl)-diethyl phosphonate(2m)
Figure BDA0001896484700000091
1H NMR(400MHz,CDCl3)δ=8.10(s,1H),7.84–7.78(m,3H),7.56–7.49(m,3H),4.29–4.21(m,4H),1.41(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=133.89,133.86,133.85,132.5,128.5,128.1,128.0,127.94,127.92,127.89,127.1,116.73,116.67,99.8,99.3,80.0,77.1,63.4,63.3,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.94ppm.
MS(EI):m/z=139.1(14),152.1(100),215.1(7),245.1(10),260.1(16),288.1(M+,34).
IR(KBr):ν=3057,2985,2932,2908,2185,1266,1159,1024,964,905,861,792,750,632,592cm-1.
HRMS(EI):calcd.for[C16H17O3P]+:288.0915,found 288.0910.
实施例14
P-((6-甲氧基-2-萘基)乙炔基)-P,P-二乙基膦酸酯
P-(2-(6-Methoxy-2-naphthalenyl)ethynyl)-diethyl phosphonate(2n)
Figure BDA0001896484700000092
1H NMR(400MHz,CDCl3)δ=8.02(s,1H),7.68(dd,J=8.5,5.1Hz,2H),7.49(d,J=8.5Hz,1H),7.16(d,J=9.0Hz,1H),7.09(s,1H),4.29–4.19(m,4H),3.90(s,3H),1.41(t,J=7.0Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=159.4,135.5,133.7,133.6,129.7,128.7,128.6,128.0,127.2,120.1,114.2,114.1,105.9,100.5,99.9,79.4,76.4,63.34,63.29,55.5,16.3,16.2ppm.
31PNMR(160MHz,CDCl3)δ=-5.65ppm.
MS(EI):m/z=139.1(21),182.1(100),244.1(9),275.1(7),290.1(19),318.1(M+,61).
IR(KBr):ν=2985,2935,2905,2179,1625,1480,1391,1263,1262,1162,1024,970,941,784,703,638cm-1.
HRMS calcd.for[C17H19O4P]+:318.1021,found 318.1015.
实施例15
P-(2-呋喃基乙炔基)-P,P-二乙基膦酸酯
P-(2-(2-Furanyl)ethynyl)-diethyl phosphonate(2o)
Figure BDA0001896484700000093
1H NMR(400MHz,CDCl3)δ=7.45(d,J=0.8Hz,1H),6.85(d,J=3.5Hz,1H),6.42(dd,J=3.4,1.7Hz,1H),4.23–4.14(m,4H),1.36(t,J=7.1Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=145.9,134.6,134.5,120.24,120.22,111.4,88.9,88.3,85.1,82.2,63.6,63.5,16.2,16.1ppm.
31PNMR(160MHz,CDCl3)δ=-6.79ppm.
MS(EI):m/z=92.1(100),155.1(15),172.1(7),185.1(17),200.1(8),228.1(M+,19).
IR(KBr):ν=3122,2987,2938,2908,2183,1471,1391,1267,1215,1162,1024,977,944,811,757cm-1.
HRMS(EI):calcd.for[C10H13O4P]+:228.0546,found 228.0546.
实施例16
P-(2-噻吩基乙炔基)-P,P-二乙基膦酸酯
P-(2-(2-Thiophenyl)ethynyl)-diethyl phosphonate(2p)
Figure BDA0001896484700000101
1H NMR(400MHz,CDCl3)δ=7.42(d,J=5.2Hz,2H),7.01(t,J=4.3Hz,1H),4.19(m,4H),1.37(t,J=7.0Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=136.1,136.0,130.7,127.5,119.33,119.27,92.8,92.3,84.0,81.0,63.44,63.38,16.23,16.16ppm.
31PNMR(160MHz,CDCl3)δ=-6.27ppm.
MS(EI):m/z=95.1(6),108.1(100),171.0(12),201.0(15),216.1(12),244.1(M+,13).
IR(KBr):ν=3077,2986,2938,2908,2174,1263,1174,1023,976,852,801,715,638cm-1.
HRMS(EI):calcd.for[C10H13O3PS]+:244.0319,found 244.0318.
实施例17
对苯基乙炔基-P,P-二甲基膦酸酯
P-(2-Phenylethynyl)-dimethyl phosphonate(2q)
1H NMR(400MHz,CDCl3)δ=7.54(d,J=7.5Hz,2H),7.44(t,J=7.4Hz,1H),7.35(t,J=7.6Hz,2H),3.83(d,J=12.3Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=132.8,132.7,130.9,128.7,119.30,119.28,100.3,99.8,78.4,75.4,53.53,53.47ppm.
31P NMR(160MHz,CDCl3)δ=-2.77ppm.
MS(EI):m/z=89(9),102(100),115(48),179(6),195(6),210(M+,22).
IR(KBr):ν=3063,3000,2956,2852,2187,1492,1450,1271,1179,1033,861,840,765,689,647cm-1.
HRMS(EI)calcd.for[C10H11O3P]+:210.0448,found 210.0440.
实施例18
对苯基乙炔基-P,P-二异丙基膦酸酯
P-(2-Phenylethynyl)-bis(1-methylethyl)phosphonate(2r)
Figure BDA0001896484700000102
1H NMR(400MHz,CDCl3)δ=7.51(d,J=7.5Hz,2H),7.40(t,J=7.4Hz,1H),7.33(t,J=7.5Hz,2H),4.84–4.71(m,2H),1.37(d,J=6.1Hz,12H)ppm.
13C NMR(100MHz,CDCl3)δ=132.53,132.50,130.6,128.6,119.9,119.8,98.4,97.9,81.4,78.4,72.40,72.35,24.0,23.9,23.7,23.6ppm.
31PNMR(160MHz,CDCl3)δ=-8.60ppm.
MS(EI):m/z=89(17),102(100),165(55),183(78),209(80),225(69),266(M+,3).
IR(KBr):ν=3063,3000,2956,2852,2187,1492,1450,1271,1179,1033,861,840,765,689,647cm-1.
HRMS(EI)calcd.for[C14H19O3P]+:266.1061,found 266.1066.
实施例19
对苯基乙炔基-P,P-二正丁基膦酸酯
P-(2-Phenylethynyl)-dibutyl phosphonate(2s)
Figure BDA0001896484700000111
1H NMR(400MHz,CDCl3)δ=7.53(d,J=7.1Hz,2H),7.42(t,J=7.5Hz,1H),7.34(t,J=7.4Hz,2H),4.13(dd,J=14.2,6.7Hz,4H),1.74–1.65(m,4H),1.48–1.38(m,4H),0.92(t,J=7.4Hz,6H)ppm.
13C NMR(100MHz,CDCl3)δ=132.7,132.6,130.7,128.6,119.7,119.6,99.4,98.8,79.9,76.9,70.0,66.9,32.3,32.2,18.8,13.6ppm.
31PNMR(160MHz,CDCl3)δ=-5.60ppm.
MS(EI):m/z=89(6),102(36),165(30),183(100),209(7),223(6),239(27),294(M+,1.5).
IR(KBr):ν=2961,2935,2869,2187,1465,1271,1066,1025,992,900,858,761,695,653cm-1.
HRMS(EI)calcd.for[C16H23O3P]+:294.1374,found 294.1379.
实施例1-实施例19的产物收率如下表所示:
Figure BDA0001896484700000112
Figure BDA0001896484700000113
Figure BDA0001896484700000121
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。

Claims (9)

1.一种P-炔基磷酸酯类化合物的合成方法,其特征在于,包括如下步骤:
在保护气体的氛围下,P-酰乙基磷酸酯类化合物、吡啶盐和有机碱在有机溶剂中进行反应,
所述P-炔基磷酸酯类化合物具有通式1所示结构,所述P-酰乙基磷酸酯类化合物具有通式2所示结构,
Figure FDA0002675405650000011
其中,R1和R2分别独立地选自:烷基、取代的烷基、芳基、取代的芳基、杂芳基、取代的杂芳基;
所述吡啶盐选自2-氯-1-甲基碘化吡啶、1,2-二甲基碘化吡啶中的至少一种;
所述有机碱为分子中不含金属的胺类化合物,所述有机碱为三乙胺。
2.根据权利要求1所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,R1和R2分别独立地选自:C1-10烷基、取代的C1-10烷基、C6-10芳基、取代的C6-10芳基、C1-9杂芳基、取代的C1-9杂芳基。
3.根据权利要求2所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,R1选自:C6-10芳基、R4取代的C6-10芳基、C1-9杂芳基、R4取代的C1-9杂芳基;R2选自:C1-10烷基、R4取代的C1-10烷基;R4选自:卤素、C1-4烷基、C1-4烷氧基、苯基。
4.根据权利要求3所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,R1选自:苯基、卤素取代的苯基、甲基取代的苯基、甲氧基取代的苯基、3、4-二亚甲氧基苯基、联苯基、萘基、甲氧基取代的萘基、呋喃基、噻吩基;R2选自:C1-4烷基。
5.根据权利要求1-4任一项所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,所述有机溶剂选自二氯甲烷、二氯乙烷中的至少一种。
6.根据权利要求1-4任一项所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,所述P-酰乙基磷酸酯类化合物、所述吡啶盐和所述有机碱的摩尔比为:1:0.8-1.2:0.8-1.2。
7.根据权利要求1-4任一项所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,所述反应的温度为10-40℃。
8.根据权利要求1-4任一项所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,所述反应的时间为2-4小时。
9.根据权利要求1-4任一项所述的P-炔基磷酸酯类化合物的合成方法,其特征在于,所述保护气体为氮气。
CN201811494343.2A 2018-12-07 2018-12-07 P-炔基磷酸酯类化合物的合成方法 Active CN109438510B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811494343.2A CN109438510B (zh) 2018-12-07 2018-12-07 P-炔基磷酸酯类化合物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811494343.2A CN109438510B (zh) 2018-12-07 2018-12-07 P-炔基磷酸酯类化合物的合成方法

Publications (2)

Publication Number Publication Date
CN109438510A CN109438510A (zh) 2019-03-08
CN109438510B true CN109438510B (zh) 2020-12-01

Family

ID=65557745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811494343.2A Active CN109438510B (zh) 2018-12-07 2018-12-07 P-炔基磷酸酯类化合物的合成方法

Country Status (1)

Country Link
CN (1) CN109438510B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061504A (zh) * 2015-09-16 2015-11-18 湖南大学 P-炔基磷酸酯类化合物的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061504A (zh) * 2015-09-16 2015-11-18 湖南大学 P-炔基磷酸酯类化合物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Base-Induced One-Pot Preparation of N- or P-Substituted Alkynes";Yang Zhang et al.,;《Eur. J. Org. Chem.》;20151110;第2015卷(第35期);第7806-7815页 *
"Facile Synthesis of 1-Alkynylphosphonates";Jong Eoun Hong et al.,;《SYNTHETIC COMMUNICATIONS》;20060815;第26卷(第8期);第1563-1567页 *
"Preparations of N and P Substituted Acetylenes Under Metal-free Conditions";Hong Chen et al.,;《Synthetic Communications》;20160616;第46卷(第17期);第1-20页 *

Also Published As

Publication number Publication date
CN109438510A (zh) 2019-03-08

Similar Documents

Publication Publication Date Title
CA3141590C (en) Catalytic cannabinoid processes and precursors
EP3083577A1 (en) Sulfonates of furan-2,5-dimethanol and (tetrahydrofuran-2,5-diyl)dimethanol and derivatives thereof
WO2021195751A1 (en) Catalytic cannabigerol processes and precursors
CN109438510B (zh) P-炔基磷酸酯类化合物的合成方法
CN104689849B (zh) 一类磷酰胺‑(伯)二级胺双功能催化剂及其合成方法
CN109320503B (zh) 苯并咪唑炔胺类化合物的无金属一锅合成方法
CN114478245A (zh) 一种手性γ-炔基-α-酮酸酯类化合物的不对称合成方法
CN115010753A (zh) 一种水相中制备磷酸化偕二氟二烯烃化合物的方法
CN111018869B (zh) 手性稠环吡喃并二氢吡咯类化合物的制备方法
CN104860911A (zh) 一种手性3,4-二氢香豆素衍生化合物合成方法
CN112125840A (zh) 基于co2参与的c-f键活化制备二芳基醚类化合物的方法
CN112299981A (zh) 一种α,α-二氟酮类衍生物的制备方法
CN111777479A (zh) 一种手性含氮杂芳环化合物的催化不对称合成方法
CN108947995A (zh) 一种多取代噁二嗪衍生物的制备方法
Krawczyk et al. Knoevenagel reaction of diethylphosphonoacetic acid: a facile route to diethyl (E)-2-arylvinylphosphonates
CN104478928A (zh) 一种α-二苯基膦取代的α,β-不饱和羧酸酯化合物及其制备与应用方法
CN113620795B (zh) 苯并环庚烯酮类化合物的合成方法
CN114181182B (zh) 一种多取代的4h-吡喃类化合物的合成方法
López-Herrera et al. Stereoselective synthesis of 2, 3-epoxy-amides by aldol-like condensation of 2, 3-O-isopropylidene-D-glyceraldehyde with N, N-diethyl diazoacetamide
CN115536530B (zh) 一种Vulgarisin型四环二萜化合物的化学全合成方法
CN109761842B (zh) α-F-β-NHAc-羰基化合物的合成方法
CN110563626B (zh) 一种1h-氮杂环丙烯类化合物及其合成方法
CN108997287B (zh) 以四氟硼酸的离子液体为氟源催化合成4-氟代四氢吡喃衍生物的方法
CN111732508B (zh) 一种螺环化合物的合成方法
CN107602316B (zh) 选择性合成烯丙基砜化合物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant